Exhibit 99.1

FOR FURTHER INFORMATION: 1275 W. Washington St.
Tempe, AZ 85281
(602) 286-5520
www.orthologic.com
Nasdaq: OLGC

Melanie Friedman (investors)
Stern Investor Relations, Inc.
(212) 362-1200
melanie@sternir.com

ORTHOLOGIC ANNOUNCES THIRD QUARTER 2006 FINANCIAL RESULTS

TEMPE, AZ — November 2, 2006 — OrthoLogic Corp. (NASDAQ: OLGC) today announced financial results for the third quarter of 2006.

OrthoLogic reported a net loss of $5.8 million, or $0.14 per share, for the third quarter of 2006, compared to a net loss of $7.6 million or $0.20 per share, for the third quarter of 2005. For the nine months ending September 30, 2006, net loss was $28.8 million, or $0.71 per share versus a net loss of $19.7 million or $0.52 per share for the nine months ended September 30, 2005. The results for the three months ended September 30, 2006 include stock based compensation expense of $0.6 million and recognition of a Chrysalin Product Platform patent impairment loss of $2.1 million. The results for the nine months ended September 30, 2006 include stock based compensation expense of $2.2 million, recognition of a Chrysalin Product Platform patent impairment loss of $2.1 million, $8.4 million of in-process research and development costs related to the acquisition of the AZX100 technology platform and recognition of income tax expense related to the recording of a valuation allowance of $1.1 million for a deferred tax asset related to an Alternative Minimum Tax credit carryover. When these factors are considered, the three- and nine-month periods ended September 30, 2006 would both show a decline in expenditure levels compared to similar periods in 2005, related primarily to the reduction in clinical activity and infrastructure expenses between 2006 and 2005.

The Company had $74.1 million in cash and investments as of September 30, 2006.

OrthoLogic originally issued guidance for 2006 for $35.0 million in cash burn. With careful adjustments to resource allocation and the interruption of the fracture repair clinical development program, the Company now forecasts a cash burn for 2006 of $15.0 million.

“The OrthoLogic management team continues to operate with an intense focus on value creation,” stated Jock Holliman, Executive Chairman of OrthoLogic. “We are performing the essential preclinical and other development work on AZX100 that will support an IND filing targeted for year-end 2007 in one of several possible indications. We have no immediate plans to re-enter clinical trials with TP508, but are continuing our development efforts to define mechanism of action and address dose and formulation issues in the fracture repair indication.”

Conference Call Information

Management will host a conference call and webcast on November 2, 2006, at 4:30 PM EST (2:30 PM MT). The call may be accessed at 800-599-9816 (domestic) or 617-847-8705 (international), with access code 36319451.

A replay will be available beginning November 2, 2006, at 6:30 PM EST until November 16, 2006, and may be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), with access code 54229516.

Additionally, the conference call will be webcast on the Investor Relations section of the Company’s website: www.orthologic.com.

About OrthoLogic

OrthoLogic is a biotechnology company committed to developing a pipeline of novel therapeutic peptides and other molecules aimed at helping patients with under-served medical conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin^® (TP508) and AZX100.

Chrysalin, the Company’s novel synthetic 23-amino acid peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need — fracture repair and diabetic foot ulcer healing. Based on the Company’s pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company focused on bone and tissue repair. The Company owns exclusive worldwide rights to Chrysalin.

AZX100 is a novel synthetic pre-clinical 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs™. AZX100 is currently being evaluated for commercially significant medical applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring and the treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100.

OrthoLogic’s corporate headquarters are in Tempe, Arizona. For more information, please visit the Company’s website: www.orthologic.com.

Statements in this press release or otherwise attributable to OrthoLogic regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include the timing and acceptability of FDA filings and the efficacy and marketability of potential products, involve risks and uncertainties that could cause actual results to differ materially from predicted results. These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of pre-clinical or clinical testing; unfavorable outcomes in our pre-clinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater efficacy or lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval of our products; our inability to successfully and cost effectively develop or outsource manufacturing and marketing of any products we are able to bring to market; changes in FDA or other regulations that affect our ability to obtain regulatory approval of our products, increase our manufacturing costs or limit our ability to market our products; our possible need for additional capital in the future to fund the continued development of our product candidates; and other factors discussed in our Form 10-K for the fiscal year ended December 31, 2005, and other documents we file with the Securities and Exchange Commission.

###

Editors’ Note: This press release is also available under the Investors section of the Company’s Web site at: www.orthologic.com.

ORTHOLOGIC CORP.
(A Development Stage Company)
CONDENSED BALANCE SHEETS
(in thousands, except per share data)
(Unaudited)

	September 30,			December 31,
	2006			2005
ASSETS
Current assets
Cash and cash equivalents	$	36,890		$	35,111
Short-term investments		27,318			46,437
Prepaids and other current assets		480			857
Total current assets		64,688			82,405
Furniture and equipment, net		403			525
Long-term investments		9,930			2,084
Deferred income taxes		—			1,106
Patents, net		—			2,223
Total assets	$	75,021		$	88,343
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	852		$	1,036
Accrued compensation		642			711
Accrued clinical		472			544
Accrued severance and restructuring costs		178			602
Other accrued liabilities		813			1,089
Total current liabilities		2,957			3,982
Deferred rent and other non-current liabilities		372			183
Total liabilities		3,329			4,165
Stockholders’ Equity
Common Stock $.0005 par value; 100,000,000 shares authorized; 41,564,291 and 38,124,742 shares issued and outstanding at 2006 and 2005, respectively		21			19
Additional paid-in capital		187,708			171,355
Accumulated deficit		(116,037	)		(87,196	)
Total stockholders’ equity		71,692			84,178
Total liabilities and stockholders’ equity	$	75,021		$	88,343

ORTHOLOGIC CORP.
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)

													As a Development
	Three months ended September 30,						Nine months ended September 30,						Stage Company
	2006			2005			2006			2005			8/5/2004 - 9/30/2006
OPERATING EXPENSES
General and administrative	$	1,414		$	1,027		$	5,567		$	3,210		$	12,355
Research and development		5,651			7,266			16,575			18,660			50,099
Other divestiture and related gains		—			—			—			(250	)		(375	)
Purchased in-process research and development		2			—			8,471			—			34,311
Total operating expenses		7,067			8,293			30,613			21,620			96,390
Interest and other income, net		(1,250	)		(700	)		(2,879	)		(1,906	)		(6,270	)
Loss from continuing operations before taxes		5,817			7,593			27,734			19,714			90,120
Income tax expense (benefit)		—			—			1,106			(12	)		356
Loss from continuing operations		5,817			7,593			28,840			19,702			90,476
Discontinued operations — net gain on the sale of the bone device business, net of taxes ($267)		—			—			—			—			(2,202	)
NET LOSS	$	5,817		$	7,593		$	28,840		$	19,702		$	88,274
Per Share Information:
Net loss, basic and diluted	$	0.14		$	0.20		$	0.71		$	0.52
Basic and diluted shares outstanding		41,545			38,025			40,496			38,019